Selected data models

You must log in to select data models for download or further analysis.

19 Search results.
Relevance Rating New first Old first

dbGaP phs001282 Genomics of Endemic Burkitt Lymphoma - Eligibility

- 4/2/23 - 5 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Ann M. Moormann, University of Massachusetts Medical School, Worcester, MA, USA MeSH: Burkitt Lymphoma,Lymphoma, Non-Hodgkin https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001282 This genomic landscape of Burkitt lymphoma represents a multimodal sequencing of tumors and control tissues and individuals to better understand the etiology, and molecular pathogenesis of Burkitt lymphoma including the roles of the associated Plasmodium falciparum malaria and EBV infections. Comprehensive sequencing set includes genomic, transcriptomic, and epigenomic datasets in concert with variable clinical phenotypes and outcome information such as anatomical presentation site, in-hospital survival rates, and EBV genome type. This deposit includes additional small RNA-seq data from endemic BL (eBL) tumors and RNA-sequencing data from sorted NK cell subsets from the peripheral blood of eBL patients. The additional small RNA-seq data are from tumor specimens from 17 eBL cases, of the previously deposited polyA RNA-seq data from 28 eBL cases (phs1282.V1). The additional RNAseq data from Fluorescence-activated cell sorting (FACS) of NK cell subsets, isolated from the peripheral blood of 7 eBL cases. *For initial transcriptome analysis see: Kaymaz et al.* "Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-specific Difference." Molecular Cancer Research, 2017. PMID 28465297 *For initial microRNA analysis see: Oduor et al.* "Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma." Frontiers in Microbiology 8, 2017. PMID 28400759 *For initial NK subsets RNA expression analysis see: Forconi et al.* "A new hope for CD56negCD16pos NK cells as unconventional cytotoxic mediators: an adaptation to chronic diseases." Frontiers in Cellular and Infection Microbiology, Submitted and Under review. *For general overview of cohort study see: Buckle et al.* "Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study." Int J Cancer. 15:1231, 2016, PMID 27136063

pht006096.v2.p1

1 itemgroup 3 items

pht006098.v2.p1

1 itemgroup 5 items

pht006099.v2.p1

1 itemgroup 12 items

pht006097.v2.p1

1 itemgroup 3 items

dbGaP phs000562 The Genetic Landscape of Mutations in Burkitt Lymphoma - pht003104.v1.p1

- 11/4/22 - 4 forms, 1 itemgroup, 2 items, 1 language
Itemgroup: pht003104
Principal Investigator: Sandeep Dave, MD, MS, Duke University, Durham, NC, USA MeSH: Burkitt Lymphoma,Lymphoma, Non-Hodgkin https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000562 Burkitt lymphoma (BL) is characterized by deregulation of *MYC*, but the contribution of other genetic mutations to the disease is largely unknown. We sequenced exomes of 59 BL tumors, 14 of which had paired normal tissue. Our work elucidates commonly occurring gene-coding mutations in Burkitt lymphoma and implicates *ID3* as a novel tumor suppressor gene.

pht003105.v1.p1

1 itemgroup 3 items

pht003107.v1.p1

1 itemgroup 5 items

pht003106.v1.p1

1 itemgroup 4 items

NCT00392834 AMC-048 Baseline Lymphoma Disease Activity and Assessment Form (LAA)

- 9/20/21 - 1 form, 3 itemgroups, 13 items, 1 language
Itemgroups: Header Module, Lymphoma Disease Activity and Assessment, Comments
NCT00392834 AMC-048 Baseline Lymphoma Disease Activity and Assessment Form (LAA) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E18FA2-327E-4AF2-E044-0003BA3F9857

AMC-048 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37)

- 8/28/17 - 1 form, 4 itemgroups, 14 items, 1 language
Itemgroups: Header - AIDS and Cancer Specimen Resource (ACSR) Procurement Form, Specimen Procurement, Contact Information, Comments
AMC-048 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E18FA2-31A3-4AF2-E044-0003BA3F9857

AMC-048 HIV Viral Load Form (F40)

- 8/28/17 - 1 form, 3 itemgroups, 9 items, 1 language
Itemgroups: Header - HIV Viral Load Form, HIV Viral Load, Comments
AMC-048 HIV Viral Load Form (F40) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E1BD21-3D3D-538C-E044-0003BA3F9857

AMC-048 Lymphoma Response Form (LYR)

- 8/28/17 - 1 form, 6 itemgroups, 20 items, 1 language
Itemgroups: Extra Nodal Involvement Evaluation, Complete Response, Complete Response Unconfirmed, Partial Response, Progressive Disease, Comments
AMC-048 Lymphoma Response Form (LYR) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=33433430-5097-2D17-E044-0003BA3F9857

AMC-048 HIV T-Cell Laboratory Values (F24)

- 8/24/17 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Header - HIV T-Cell Laboratory Values, T-cell Laboratory Values
AMC-048 HIV T-Cell Laboratory Values (F24) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E1BD21-3CF6-538C-E044-0003BA3F9857

Enrollment HIV associated Burkitt Lymphoma AMC-048 NCT00392834

- 8/4/15 - 1 form, 5 itemgroups, 12 items, 1 language
Itemgroups: Header Module, Inclusion Criteria, Exclusion Criteria, Disease Risk, Comments
AMC-048 ENR (Enrollment) NCT00392834 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E18FA2-33FA-4AF2-E044-0003BA3F9857

AMC-048 Adverse Events Form (ADV) NCT00392834

- 7/8/15 - 1 form, 3 itemgroups, 18 items, 1 language
Itemgroups: Header, Adverse event assessment, Comments
AMC-048 Adverse Events Form (ADV) NCT00392834 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E18FA2-31FB-4AF2-E044-0003BA3F9857

AMC-048 Off Study Summary (F50) NCT00392834

- 6/3/15 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: Ccrr Module For Off Study Summary - Rf50
AMC-048 Off Study Summary (F50) NCT00392834 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E1BD21-3F26-538C-E044-0003BA3F9857

AMC-048 Missed Visit Form (F35) NCT00392834

- 6/3/15 - 1 form, 3 itemgroups, 6 items, 1 language
Itemgroups: Header Module, Missed Visit information, Comments
AMC-048 Missed Visit Form (F35) NCT00392834 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E1BD21-3EC8-538C-E044-0003BA3F9857

AMC-048 Quantitative Immunoglobulins Form (QIM) NCT00392834

- 6/3/15 - 1 form, 3 itemgroups, 6 items, 1 language
Itemgroups: Header Module, Quantitative Immunoglobulins, Comments
AMC-048 Quantitative Immunoglobulins Form (QIM) NCT00392834 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E1BD21-4052-538C-E044-0003BA3F9857

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial